Efficacy of efgartigimod in the treatment of autoimmune encephalitis: a systematic review.

Neurol SciSep 11, 2026 (epub)
Clinical ResearchNeurologyPsychiatryOpen access

Ping Tang, Kaiqiang Xiao, Yi He et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Autoimmune encephalitis (AE) encompasses a group of inflammatory disorders of the brain parenchyma mediated by autoimmune mechanisms. Currently, first-line immunotherapy for AE typically involves corticosteroids, intravenous immunoglobulin, and plasma exchange or immune adsorption.

Reported results

Twelve studies were included, comprising nine case reports or series, two case control studies, and one cross‑sectional study. A total of 77 patients with AE were enrolled. The majority (76/77) demonstrated significant clinical improvement following efgartigimod treatment, and no serious adverse events were observed.

Authors' conclusions

Efgartigimod holds potential as a safe and effective adjunctive therapy for AE patients, either as adjunctive treatment after inadequate responses to first-line or second-line therapies or as concomitant add-on therapy combined with first-line treatment.

Source

PubMed · PMID 42726141Free full text on PubMed Central

Published in Neurol Sci. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.